Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Vadadustat Patent Expiration

Vadadustat was first introduced by Akebia Therapeutics Inc in its drug Vafseo on Mar 27, 2024.


Vadadustat Patents

Given below is the list of patents protecting Vadadustat, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vafseo US10149842 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Nov 14, 2034 Akebia
Vafseo US11065237 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Nov 14, 2034 Akebia
Vafseo US11324734 Compositions and methods for treating anemia Mar 31, 2036 Akebia
Vafseo US11844756 Compositions and methods for treating anemia Mar 31, 2036 Akebia
Vafseo US11857543 Compositions and methods for treating anemia Jun 09, 2034 Akebia
Vafseo US7811595 Prolyl hydroxylase inhibitors and methods of use Mar 13, 2028 Akebia
Vafseo US8323671 Prolyl hydroxylase inhibitors and methods of use Apr 03, 2028 Akebia
Vafseo US8343952 Prolyl hydroxylase inhibitors and methods of use Aug 14, 2027 Akebia
Vafseo US8598210 Prolyl hydroxylase inhibitors and methods of use Jun 26, 2027 Akebia
Vafseo US8940773 Prolyl hydroxylase inhibitors and methods of use Jun 26, 2027 Akebia
Vafseo US9701636 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Nov 14, 2034 Akebia
Vafseo US9987262 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Nov 14, 2034 Akebia
Vafseo USRE47437 Prolyl hydroxylase inhibitors and methods of use Jun 26, 2027 Akebia


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vadadustat's patents.

Given below is the list recent legal activities going on the following patents of Vadadustat.

Event Date Patent/Publication
Patent litigations
Mail Patent eCofC Notification 11 Jun, 2024 US8940773
Patent eCofC Notification 11 Jun, 2024 US8940773
Email Notification 11 Jun, 2024 US8940773
Recordation of Patent eCertificate of Correction 11 Jun, 2024 US8940773
Initial letter Re: PTE Application to regulating agency 21 May, 2024 US8940773
Post Issue Communication - Certificate of Correction 21 May, 2024 US8940773
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8940773
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US7811595(Litigated)
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8343952(Litigated)
Patent Term Extension Application under 35 USC 156 Filed 17 May, 2024 US8598210(Litigated)



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳